Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference
14 avr. 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, April 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Announces Refresh to Board of Directors
30 mars 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development...
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
29 mars 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash. and VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development...
Achieve Life Sciences Announces Granting of New Hire Inducement Award
17 mars 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash. and VANCOUVER, British Columbia, March 17, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development...
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update
16 mars 2023 16h05 HE
|
Achieve Life Sciences
SEATTLE, Wash. and VANCOUVER, British Columbia, March 16, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
08 mars 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
03 mars 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash. and VANCOUVER, British Columbia, March 03, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023
02 mars 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
07 févr. 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference
02 févr. 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...